Literature DB >> 15651744

Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms.

David Nolan1, Simon Mallal.   

Abstract

The availability of durable, effective antiretroviral therapy for HIV-infected patients has fundamentally altered the prognosis of this disease and has also increased awareness that long-term drug toxicities have the potential to cause significant morbidity and even mortality in this patient population. The long-term use of nucleoside analogue reverse transcriptase inhibitor (NRTI) drugs has been associated with a number of clinically relevant toxicities including hyperlactataemia and lactic acidosis, neuropathy, pancreatitis and, more recently, a syndrome of pathological loss of subcutaneous fat tissue (lipoatrophy). Importantly, the toxicity profile of each NRTI drug within this class is unique in terms of the overall risk of long-term complications, as well as the tissue specificity of its toxic effects. In this review, the clinical manifestations, risk factors and pathological basis for NRTI-associated toxicity syndromes are explored, with an emphasis on clinical assessment and management.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15651744

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  35 in total

Review 1.  Antiretroviral therapy: current drugs.

Authors:  Alice K Pau; Jomy M George
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

2.  New HIV Drugs in Development, 2005.

Authors:  Jeffrey P Nadler; Michael C Phillips
Journal:  Curr Infect Dis Rep       Date:  2005-05       Impact factor: 3.725

Review 3.  [Options in HIV therapy: present and future].

Authors:  J Röling; R Draenert; F D Goebel
Journal:  Internist (Berl)       Date:  2005-08       Impact factor: 0.743

4.  Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy.

Authors:  Asha R Kallianpur; Todd Hulgan
Journal:  Pharmacogenomics       Date:  2009-04       Impact factor: 2.533

Review 5.  HIV-associated cellular senescence: A contributor to accelerated aging.

Authors:  Justin Cohen; Claudio Torres
Journal:  Ageing Res Rev       Date:  2016-12-23       Impact factor: 10.895

Review 6.  HIV-associated neurological disorders: a guide to pharmacotherapy.

Authors:  Ik L Tan; Justin C McArthur
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

7.  Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial.

Authors:  Bruce R Schackman; Callie A Scott; Paul E Sax; Elena Losina; Timothy J Wilkin; John E McKinnon; Susan Swindells; Milton C Weinstein; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2007-09-04       Impact factor: 9.079

8.  A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.

Authors:  Matt S Anderson; Sauzanne Khalilieh; Ka Lai Yee; Rachael Liu; Li Fan; Matthew L Rizk; Vedangi Shah; Azra Hussaini; Ivy Song; Lisa L Ross; Joan R Butterton
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

Review 9.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

10.  Quantification of mitochondrial toxicity in HIV-infected individuals by quantitative PCR compared to flow cytometry.

Authors:  Thor A Wagner; Chen-Han Lin; Nicole H Tobin; Hélène C F Côté; Derek D Sloan; Keith R Jerome; Lisa M Frenkel
Journal:  Cytometry B Clin Cytom       Date:  2012-10-08       Impact factor: 3.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.